Cemiplimab. a drug that belongs to a class of agents known as immune checkpoint inhibitors, Has been approved by the FDA for patients with an advanced form of cutaneous squamous cell carcinoma (SCC), a common type of skin cancer. This is the first agent to be approved by FDA specifically for advanced SCC.
To read more about this drug, click here.
No comments:
Post a Comment